Bard invests in urology ultrasound
Interventional equipment vendor C.R. Bard has invested $2 million for a minority equity interestin Diagnostic Ultrasound of Redmond, WA. Bard's patient care andurology divisions will also market Diagnostic Ultrasound's BladderScanBVI 2500 scanner in the
Interventional equipment vendor C.R. Bard has invested $2 million for a minority equity interestin Diagnostic Ultrasound of Redmond, WA. Bard's patient care andurology divisions will also market Diagnostic Ultrasound's BladderScanBVI 2500 scanner in the U.S.
BladderScan is a noninvasive, nonimaging ultrasound devicethat provides measurements of bladder volume. The measurementtechnique provides a lower cost and less risky alternative tourinary catheters often used for bladder diagnosis. Bard is amajor catheter supplier.
According to estimates from the Centers for Disease Control,the cost to the U.S. health-care system of hospital-induced infectionsamounts to over $2 billion annually. About 80% of these infectionsare induced during urinary catheterization.
Diagnostic Ultrasound expects sales to double this year, aidedby Bard's investment, the Bard marketing agreement, an equivalentinvestment by another unnamed source, and expanded internationalbusiness. The company's other product is Versadopp 10, a pen-sizedDoppler blood-flow sensor used to evaluate the risk of strokeor peripheral artery disease and to assist in surgery.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Ultrasound-Guided Thermal Ablation Shows Low Recurrence of Thyroid Carcinoma at Five Years
June 16th 2025In a meta-analysis involving over 2,200 patients with T1NoMo papillary thyroid carcinoma, researchers noted 2 percent recurrence and no cases of lymph node metastasis five years after ultrasound-guided thermal ablation.
